Healthcare / Medical Instruments & SuppliesShenzhen
$6.43
+0.02 (+0.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-638.4M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
N/A
•EV/EBITDA
53.9x
↑ROE
-10.6%
↓Gross Margin
15.7%
↓Debt/Equity
0.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.4%
FCF CAGR
—
FCF margin
-1.7%
FCF / Net income
0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.74B · net income $-758.9M · FCF $-95.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.74B | $5.74B | $6.25B | $4.93B | $4.90B |
| Net Income | $-758.9M | $-758.9M | $-445.6M | $-568.4M | $-372.3M |
| EBITDA | $183.4M | $183.4M | $403.4M | $82.4M | $212.6M |
| EPS | -0.76 | -0.76 | -0.44 | -0.57 | -0.37 |
| Gross Margin | 15.7% | 15.7% | 16.5% | 12.3% | 10.2% |
| Operating Margin | -2.9% | -2.9% | -2.2% | -9.5% | -10.7% |
| Net Margin | -13.2% | -13.2% | -7.1% | -11.5% | -7.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.72 | 0.72 | 0.45 | 0.40 | 0.30 |
| Current Ratio | 0.87 | 0.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-95.3M | $-95.3M | $-638.4M | $-847.0M | $-402.4M |
| Returns | |||||
| ROE | -10.6% | -10.6% | -5.3% | -6.0% | -3.5% |
| Valuation | |||||
| EV/EBITDA | 53.92 | 53.92 | 16.57 | 112.72 | 43.23 |
| P/B | 0.90 | 0.90 | 0.59 | 0.70 | 0.76 |
| Growth & Yield | |||||
| Revenue Growth | -8.2% | -8.2% | 26.9% | 0.5% | — |
| EPS Growth | -72.7% | -72.7% | 22.8% | -54.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.44 → -0.76
Residual
+19.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.